IDEXX Laboratories, Inc. (NASDAQ:IDXX) CEO Jonathan W. Ayers sold 2,160 shares of the stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $167.03, for a total value of $360,784.80. Following the completion of the sale, the chief executive officer now directly owns 1,077,112 shares of the company’s stock, valued at $179,910,017.36. The sale was disclosed in a filing with the SEC, which is available at this link.
Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) opened at $173.24 on Friday. IDEXX Laboratories, Inc. has a one year low of $116.54 and a one year high of $173.82. The company has a debt-to-equity ratio of -12.48, a quick ratio of 0.77 and a current ratio of 0.95. The firm has a market capitalization of $15,109.82, a PE ratio of 56.06, a PEG ratio of 2.34 and a beta of 0.42.
IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The company had revenue of $492.00 million during the quarter, compared to the consensus estimate of $492.94 million. During the same period last year, the business earned $0.62 EPS. The business’s quarterly revenue was up 9.7% on a year-over-year basis. equities research analysts anticipate that IDEXX Laboratories, Inc. will post 3.24 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently bought and sold shares of IDXX. D.A. Davidson & CO. raised its stake in shares of IDEXX Laboratories by 160.4% during the 2nd quarter. D.A. Davidson & CO. now owns 625 shares of the company’s stock worth $100,000 after purchasing an additional 385 shares in the last quarter. Sun Life Financial INC raised its stake in shares of IDEXX Laboratories by 9,085.7% during the 2nd quarter. Sun Life Financial INC now owns 643 shares of the company’s stock worth $104,000 after purchasing an additional 636 shares in the last quarter. BB&T Investment Services Inc. purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter worth about $104,000. Zions Bancorporation purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter worth about $162,000. Finally, Coastline Trust Co purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter worth about $202,000. 86.61% of the stock is owned by institutional investors.
IDXX has been the subject of several research analyst reports. Canaccord Genuity reissued a “buy” rating and issued a $180.00 price objective on shares of IDEXX Laboratories in a research note on Friday, October 6th. Zacks Investment Research downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, October 18th. Stifel Nicolaus reissued a “buy” rating and issued a $185.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, October 24th. Aegis reissued a “sell” rating on shares of IDEXX Laboratories in a research note on Friday, December 8th. Finally, BidaskClub downgraded IDEXX Laboratories from a “hold” rating to a “sell” rating in a research note on Saturday, December 16th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. IDEXX Laboratories has an average rating of “Hold” and a consensus target price of $173.67.
WARNING: “Insider Selling: IDEXX Laboratories, Inc. (IDXX) CEO Sells $360,784.80 in Stock” was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.thelincolnianonline.com/2018/01/14/insider-selling-idexx-laboratories-inc-idxx-ceo-sells-360784-80-in-stock.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.